Company Information

Location

Copenhagen, Denmark

Website

twelve.bio

Twelve Bio was founded based on research conducted at the Novo Nordisk Foundation (NNF) Center for Protein Research at the University of Copenhagen. With support from the Creation House program sponsored by the BioInnovation Institute in Copenhagen and seed investment from Arix Bioscience, Twelve Bio advanced the foundational insights from X-ray crystallography and cryogenic electron microscopy to further engineer and evolve CRISPR-Cas12a into wholly novel sequences with unique properties useful for a range of DNA editing strategies. This engineering builds on the natural advantages of Cas12a, including small size, high specificity, multiplexing and ability to target sections of DNA not amenable to other Cas nucleases.

In January 2023 it was announced that TwelveBio had entered into a definitive agreement to be acquired by Ensoma (www.ensoma.com) as part of an all-share transaction in connection with a financing round.